Arthex Biotech Announces Closing Of €42 M Series B Financing To Advance Atx-01, Its Novel Treatment For Myotonic Dystrophy Type 1 (Dm1)
Arthex Biotech Announces Closing Of €42 M Series B Financing To Advance Atx-01, Its Novel Treatment For Myotonic Dystrophy Type 1 (Dm1)
05/03/23, 11:02 AM
Location
valenciaMoney raised
€42 million
Industry
therapeutics
biotechnology
health care
Round Type
series b
Investors
The Centre For The Development Of Industrial Technology, Cdti, Ad Bio Partners, Invivo Capital, Sound Bioventures, Hadean Ventures, European Innovation Council, Columbus Venture Partners
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs announced the closing of its €42 million Series B financing round led by Columbus Venture Partners, with participation from new investors, the European Innovation Council (EIC), Hadean Ventures, and Sound Bioventures. Existing investors Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI) through its Innvierte program, also participated in the financing.
Company Info
Location
valencia, valencian community, spain
Additional Info
ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs.
ARTHEx has developed its proprietary technology, the ENTRY ™ platform, that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role.
The first investigational product from this platform is ATX-01, an antimiR in preclinical development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis.
To learn more about Arthex Biotech, please visit us at www.arthexbiotech.com